A Study of Safety and Efficacy Comparing ABT-874 Versus Methotrexate in Subjects With Moderate to Severe Plaque Psoriasis

AbbVie

Status and phase: Completed; Phase 3

Conditions: Psoriasis

Treatments: Drug: Methotrexate; Drug: ABT-874

Study type: Interventional

Funder types: Industry

Identifiers

NCT00679731

M10-255

2007-004687-47 (EudraCT Number)

Details and patient eligibility

About

This study is being conducted to compare the efficacy of ABT-874 versus Methotrexate in subjects with moderate to severe plaque psoriasis.

Full description

This study is only being conducted in the EU and Canada

Enrollment: 317 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Diagnosis of Psoriasis for 6 MO.. BSA 10%, PASI 12 or above, PGA 3 or above

Exclusion criteria

• Previous exposure to anti-IL 12

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

317 participants in 2 patient groups

A

Experimental group

Description:

ABT-874

Treatment:

Drug: ABT-874

B

Active Comparator group

Description:

Methotrexate

Treatment:

Drug: Methotrexate